Posts Tagged ‘chemo’

System Effected by Possible Side Effects of Sorafenib

Gastrointestinal

Gastrointestinal (GI) side effects including diarrhea (43%), increased lipase (41%), increased amylase (30%), nausea (23%), anorexia (16%), vomiting (16%), and constipation (15%) have been reported. Common side effects have included mucositis, stomatitis, (including dry mouth and glossodynia), dyspepsia, and dysphagia. Uncommon side effects have included pancreatitis, GI reflux, and gastritis. In addition, GI perforation has been reported in less than 1% of patients receiving sorafenib and not always associated with apparent intra- abdominal tumor.

Dermatologic

Dermatologic side effects including rash/desquamation (40%), Hand-foot skin reaction (30%), alopecia (27%), pruritus (19%), and dry skin (11%) have been reported. Very common side effects have included erythema. Common side effects have included exfoliative dermatitis, acne, and flushing. Scalp dysesthesia and subungual splinter hemorrhages (characterized by straight black or red lines under the nails) have been reported. Uncommon side effects have included folliculitis, eczema, and erythema multiforme. Three cases of keratoacanthomas and two cases of sorafenib-induced eruptive melanocytic lesions have also been reported.

Cardiovascular

Cardiovascular side effects including hypertension (17%) have been reported. Uncommon side effects have included hypertensive crisis, congestive heart failure, myocardial ischemia, and/or infarction. Cardiac failure, thromboembolism, and arrhythmia have been reported infrequently.

Hematologic

Hematologic side effects including Hypoalbuminemia (49%), hemorrhage (15%) (i.e., gastrointestinal, respiratory tract and rarely cerebral hemorrhage) have been reported. Common side effects have included anemia and thrombocytopenia. Uncommon side effects have included abnormal international normalized ratio (INR) results. Cases of erythrocytosis have also been reported.

Respiratory

Respiratory side effects including dyspnea (14%) and cough (13%) have been reported. Common side effects have included hoarseness. Uncommon side effects have included rhinorrhea.

Nervous System

Nervous system side effects including sensory neuropathy (13%) and headache (10%) have been reported. Common side effects have included tinnitus. Cerebral hemorrhage, transient ischemic attack, and reversible posterior leukoencephalopathy have also been reported infrequently.

Musculoskeletal

Musculoskeletal side effects including joint pain (10%) have been reported. Common side effects have included arthralgia and myalgia.

Immunologic

Immunologic side effects have very commonly included leukopenia and lymphopenia. Common side effects have included neutropenia.

Hypersensitivity

Hypersensitivity side effects including skin reactions and urticaria have been reported.

Metabolic

Metabolic side effects including weight loss (10%), transient increases in transaminases, and hypophosphatemia have been commonly reported. Uncommon side effects have included dehydration, hyponatremia, transient increases in alkaline phosphatase, increased bilirubin (including jaundice), and hypothyroidism.

Psychiatric

Psychiatric side effects have commonly included depression.

Genitourinary

Genitourinary side effects have commonly included erectile dysfunction. Uncommon side effects have included gynecomastia.

Renal

Renal side effects including acute renal failure have been reported infrequently.

Hepatic

Hepatic side effects including liver dysfunction have been reported in at least 10% of patients.

Other

Other side effects including fatigue (37%) and abdominal pain (11%) have been reported. Very common side effects have included asthenia and pain (including mouth, bone, and tumor pain). Common side effects have included decreased appetite, influenza-like illness, and pyrexia. Uncommon side effects have included infection.

Broccoli To The Rescue

There are naturally occurring substances that block precisely this undesired NF-KB pathway and thus make the dangerous cells vulnerable: vegetables from the cruciferous family such as broccoli and cauliflower possess a high content of sulforaphane, an anti-cancer compound.

The experiments show that sulforaphane prevents the activation of the NF-kB pathway by sorafenib. The combination treatment reinforces the effect of sorafenib without causing additional side effects.

The invasive potential of cancer cells was prevented – metastasis was completely blocked in cell culture experiments. “We assume that nutrition may be a suited approach to break therapy resistance of cancer stem cells and thus make tumor treatment more effective,” Professor Herr suggested

You Must Remember, the medical advice from your doctor, leaves out one fact-food is medicine.

Chemotherapy Feeds Cancer, sounds strange, now learn the truth.

Have you ever wondered why advance cancer treatment fails to halt the spread of a tumor?

Cancer Feeds on

The reasons why mainstream cancer treatments so often fail, is that chemotherapy may be a cancer’s friend. Chemotherapy is a doubled edge sword. The effects of the treatment are deadly for many reasons.

The treatment alone can kill you and many times does. But, the deadly effects don’t stop there. Halting the spread of these cells has always been the Achilles’ heal of the cancer industry.

The public has a healthy fear of chemo and radiation treatment. Why people deteriorate on those protocols are three fold. One, the treatment many times doesn’t slow the spread, two it breaks down the immune system, and three it feeds the cancer cells.

Cancer can become immune to chemotherapy and use the drugs for a food supply. This next reason is the icing on the cake.

Researchers with the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center and UAB Department of Chemistry have won an $805,000 grant from the U.S, Department of Defense Breast Cancer Research Program to study whether dead cancer cells left over after treatment encourage Cancer’s spread to other parts of the body.

The research centers on examining inactivated or altered genetic material (DNA) left in the body after breast-cancer cells are exposed to chemotherapy. UAB researches say the resulting altered DNA may be the factor that activates the spread of living cancer cells to distant locations in the body- a process called metastasis-through a specific molecular pathway.

“What if by killing cancer cells with chemotherapy we inadvertently induce DNA structures that make surviving cancers cells more invasive? The idea is tough to stomach,” said Katri Selender, M.D, PhD, and assistant professor of the UBA Division of Hematology and oncology and co-principal researcher on the grant.

Cellular Health A Comprehensive View:

httpv://www.youtube.com/watch?v=i9qejUElQKw